Cargando…

Retrospective Real-Life Data, Efficacy and Safety of Vismodegib Treatment in Patients with Advanced and Multiple Basal Cell Carcinoma: 3-Year Experience from a Spanish Center

Background: Basal cell carcinoma (BCC) is the most common type of skin cancer and can represent a therapeutic challenge in patients with locally advanced disease. Vismodegib is a hedgehog pathway inhibitor approved by the FDA for use in this type of tumor. We present a case series to describe our ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ayén-Rodríguez, Angela, Linares-González, Laura, Llamas-Segura, Carlos, Almazán-Fernández, Francisco Manuel, Ruiz-Villaverde, Ricardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218270/ https://www.ncbi.nlm.nih.gov/pubmed/37239551 http://dx.doi.org/10.3390/ijerph20105824

Ejemplares similares

Vismodegib treatment in advanced basal cell carcinomas: Real‐life experience
por: Villani, Alessia, et al.
Publicado: (2021)

Herpes zóster oftálmico en el contexto de la pandemia por COVID-19
por: Ayén-Rodriguez, Angela, et al.
Publicado: (2021)

Vismodegib: the Proof of Concept in Basal Cell Carcinoma
por: Berrada, Narjiss, et al.
Publicado: (2014)

Real World Data on Efficacy and Safety of Vismodegib in Greek Patients with Advanced, Multiple and Metastatic Basal Cell Carcinoma
por: Sgouros, Dimitrios, et al.
Publicado: (2022)

Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib
por: Su, Maxwell G., et al.
Publicado: (2020)

Treatment of Locally Advanced Basal Cell Carcinomas with Vismodegib
por: Mastronardi, Luis, et al.
Publicado: (2021)

Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia
por: Mesti, Tanja, et al.
Publicado: (2022)

Analysis of efficacy and safety of vismodegib therapy in patients with advanced basal cell carcinoma – real world multicenter cohort study
por: Słowińska, M., et al.
Publicado: (2022)

Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma
por: Chang, Anne Lynn S., et al.
Publicado: (2016)

Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis
por: Gutzmer, Ralf, et al.
Publicado: (2021)

Penfigoide ampolloso sobre herida quirúrgica. ¿Una complicación emergente en el anciano?
por: Ródenas-Herranz, Teresa, et al.
Publicado: (2021)

Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond
por: Cowey, C. Lance
Publicado: (2013)

Investigational agents in metastatic basal cell carcinoma: focus on vismodegib
por: Batty, Nicolas, et al.
Publicado: (2012)

Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib
por: Martins, Pedro Carvalho, et al.
Publicado: (2019)

Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome
por: Weiss, Glen J., et al.
Publicado: (2011)

Benefit–risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinoma
por: García Ruiz, Antonio J, et al.
Publicado: (2022)

Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials
por: Chang, Anne Lynn S., et al.
Publicado: (2016)

18-FDG PET/CT assessment of basal cell carcinoma with vismodegib
por: Thacker, Curtis A, et al.
Publicado: (2012)

Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma
por: Macha, Muzafar A, et al.
Publicado: (2013)

Vismodegib: A smoothened inhibitor for the treatment of advanced basal cell carcinoma
por: Aditya, Suruchi, et al.
Publicado: (2013)

Rapid response to vismodegib in a patient with advanced basal cell carcinoma
por: Vornicova, Olga, et al.
Publicado: (2015)

Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face
por: Block, Alec M., et al.
Publicado: (2015)

Granulation tissue masquerading as basal cell carcinoma after treatment with vismodegib
por: Miedema, Jayson, et al.
Publicado: (2017)

Vismodegib and orbital excision for treating locally advanced basal cell carcinoma
por: Hogarty, Daniel T, et al.
Publicado: (2018)

Gene-Related Response of Basal Cell Carcinoma to Biologic Treatment with Vismodegib
por: Sternfeld, Amir, et al.
Publicado: (2020)

Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS
por: KAATZ, Martin, et al.
Publicado: (2022)

Multicenter Retrospective Andalusian Study of the Use of Sonidegib for the Treatment of Local Advanced Basal Cell Carcinoma in Real Clinical Practice
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2023)

Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

Vismodegib for treatment of periocular basal cell carcinoma – 6-year experience from a tertiary cancer center()()
por: Xavier, Catarina, et al.
Publicado: (2021)

Vismodegib-resistant basal cell carcinomas in basal cell nevus syndrome: Clinical approach and genetic analysis
por: Sinx, Kelly A.E., et al.
Publicado: (2018)

Activation of AMPK sensitizes medulloblastoma to Vismodegib and overcomes Vismodegib‐resistance
por: Gampala, Silpa, et al.
Publicado: (2021)

Giant morphea-form basal cell carcinoma of the umbilicus: Successful debulking with vismodegib
por: Orduz Robledo, Mariana, et al.
Publicado: (2018)

A Non-Interventional Study on Vismodegib for Basal Cell Carcinoma in Swedish Patients
por: Bendsöe, Niels, et al.
Publicado: (2023)

A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma
por: Odom, Dawn, et al.
Publicado: (2017)

Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma
por: Yurchenko, Andrey A., et al.
Publicado: (2022)

Non-surgical Management of Locally Advanced Basal Cell Carcinoma of the Upper Extremity With Vismodegib
por: Swisher, Austin R, et al.
Publicado: (2022)

Complete pathologic clearance with vismodegib in advanced basal cell carcinoma of the scalp with cranial invasion
por: Dodson, Joseph, et al.
Publicado: (2022)

Characterization of intractable diarrhea resulting from vismodegib treatment for basal cell nevus syndrome
por: Patel, Ashmi, et al.
Publicado: (2022)

Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma
por: Bertrand, Nicolas, et al.
Publicado: (2021)

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
por: Sekulic, Aleksandar, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0305duns75smq38itv4m0epjtf